When a panel of experts couldn’t agree on the merit of Sanofi and Lexicon’s SGLT1/2 inhibitor Zynquista for Type 1 diabetes, Sanofi stood behind the drug. But now the FDA has handed down its decision against it. More: FDA stiff-arms
read moreAnalysts with Cortellis expect seven blockbuster drug launches in markets across the world this year. AbbVie’s upadacitinib leads the pack with expected 2023 sales of $2.2 billion. More: From AbbVie's upadacitinib to new gene therapies: Pharma's 2019 blockbuster launches, ranked
read moreExactly eight years into its full ownership of Alcon, Novartis will officially say goodbye to the eye care business on April 9. The spinoff follows Novartis’ recent sale of its stake in a GlaxoSmithKline consumer joint venture and some Sandoz
read moreAmid a national conversation over drug prices, Democrats are raising concern with the trade deal negotiated between the U.S., Canada and Mexico. More: Democrats push back at North American trade deal over biologic drug exclusivity Source: fierce
read moreThe a three-year follow-up study comparing Ontruzant to Herceptin has found the biosimilar to be just as successful. More: Long-term data shows promise in breast cancer biosimilar Source: News
read more£23 million of government funding has been awarded to cutting edge health projects. More: £23 million funding for cutting edge health projects Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals